ArticlePloS one2026
Production of anti-inflammatory and antidiabetic oligosaccharides from okra mucilage through one-step microbial fermentation.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plant-based natural products are increasingly being explored as safer and more sustainable alternatives than synthetic drugs for controlling globally rising chronic health conditions, including inflammation and diabetes. Microbial fermentation has long been used to enhance the value and bioactivity of natural products. In this study, we produced bioactive oligosaccharides from okra (Abelmoschus esculentus) mucilage polysaccharides using a sustainable one-step Pichia kudriavzevii-mediated fermentation approach. The oligosaccharide fractions separated by size-exclusion chromatography primarily contained uronic acids, pentoses, and hexoses. In vitro assays showed that these oligosaccharides possess notable anti-inflammatory and antidiabetic potential. Among the fractions, ODF91 exhibited the strongest membrane-stabilizing activity, providing 92.86% protection of the erythrocyte membrane, comparable to that of the standard anti-inflammatory drug. ODF91, at 200 mg/kg, markedly reduced paw edema by 94.69% in the carrageenan-induced mouse model, supporting preliminary in vivo anti-inflammatory activity. ODF91, at 200 mg/kg, also lowered blood glucose levels in streptozotocin-induced diabetic mice by 86.91%, followed by ODF83 and ODF84, suggesting promising preliminary antihyperglycemic activity. Furthermore, lipid profile parameters significantly improved in diabetic mice after treatment with these oligosaccharides. Collectively, these results suggest that the fermented okra-derived oligosaccharides possess promising anti-inflammatory and antidiabetic properties and highlight microbial fermentation as a scalable strategy for converting underutilized plant polysaccharides into value-added bioactive products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.